Amgen stock gains 3.13 percent on October 7

Published on 10/07/2026 at 17:05 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Amgen stock traded at USD 415.18 on October 7, 2026, with a USD 224.1 billion market capitalization. Q2 revenue reached USD 10.05 billion, up 9.5 percent year over year.

Bauhaus-Poster mit geometrischen Formen, Molekülstrukturen und großem Schriftzug BIOTECH in Primärfarben — Amgen Inc. (ISIN US0311621009) inspirierte dieses geometrische Bauhaus-Poster mit dem Sektor-Schriftzug BIOTECH, Illustration mit AI erstellt.

Amgen (ISIN US0311621009) carried a market capitalization of USD 224.1 billion on October 7, 2026, as its stock gained 3.13 percent in intraday Nasdaq trading. The move keeps the biotechnology company in a valuation debate shaped by solid second-quarter growth and a consensus target below the market quote.

Q2 revenue keeps growth in view

For Q2 2026, Amgen reported revenue of USD 10.05 billion, up 9.5 percent from the year-earlier period, according to MarketBeat on October 6, 2026. The figure also exceeded the USD 9.43 billion analyst revenue expectation cited in the same report, giving the current price move an operating backdrop rather than a purely technical explanation.

The latest quarter ended June 30, 2026, with Amgen posting USD 2.375 billion in net income, diluted GAAP EPS of USD 4.37 and an operating margin of 35 percent, according to Financial News in its September 22, 2026 report.

Consensus stays below the quote

MarketBeat listed a Hold consensus from 30 analysts on October 6, 2026, with an average price target of USD 385.25. That average stood USD 29.93 below Amgen's intraday quote, a gap that makes execution and pipeline delivery central to the stock's next assessment.

The analyst mix comprised one Strong Buy, eleven Buy, fifteen Hold and three Sell ratings, according to MarketBeat. The distribution points to a divided view: recent revenue growth is measurable, but the average target remains below the live market level.

Next earnings date is November 3

Amgen's next scheduled checkpoint is its Q3 2026 earnings announcement on November 3, 2026, according to the Yahoo Finance earnings calendar. The listed consensus EPS estimate is USD 5.78, creating a clear numerical checkpoint against the Q2 result and the company's recently reported revenue trajectory.

Stock remains below yearly high

Amgen was trading at USD 415.18 on NASDAQ on October 7, 2026 at 11:04 a.m. ET, with a session range of USD 401.85 to USD 415.79 and a volume of 662,752 shares. The quote was 7.12 percent below the 52-week high of USD 447.03 and above the 52-week low of USD 288.00.